NasdaqGS:NUVLBiotechs
How Investors May Respond To Nuvalent (NUVL) FDA Review Of Brain-Targeted ROS1 Lung Cancer Drug
Nuvalent announced that the FDA accepted its New Drug Application for zidesamtinib in previously treated ROS1-positive NSCLC, with new ARROS-1 data presented at the April 2026 AACR meeting showing clinically meaningful activity and a consistent safety profile in heavily pre-treated patients.
A key insight is zidesamtinib’s targeted design for brain penetrance and activity against hard-to-treat ROS1 resistance mutations, including G2032R, in patients who lack effective ROS1 TKI options.
We’ll...